Xvivo Perfusion AB (OSTO:XVIVO) Cash-to-Debt : 16.54 (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Xvivo Perfusion AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Xvivo Perfusion AB's cash to debt ratio for the quarter that ended in Mar. 2024 was 16.54.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Xvivo Perfusion AB could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Xvivo Perfusion AB's Cash-to-Debt or its related term are showing as below:

OSTO:XVIVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16 Med: 52.26 Max: No Debt
Current: 16.54

During the past 12 years, Xvivo Perfusion AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.16. And the median was 52.26.

OSTO:XVIVO's Cash-to-Debt is ranked better than
76.74% of 860 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs OSTO:XVIVO: 16.54

Xvivo Perfusion AB Cash-to-Debt Historical Data

The historical data trend for Xvivo Perfusion AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Xvivo Perfusion AB Cash-to-Debt Chart

Xvivo Perfusion AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

28.68

49.12

69.69

24.61

17.36

Xvivo Perfusion AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.68	6.22	23.28	17.36	16.54

Competitive Comparison of Xvivo Perfusion AB's Cash-to-Debt

For the Medical Devices subindustry, Xvivo Perfusion AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xvivo Perfusion AB's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Cash-to-Debt falls into.

Xvivo Perfusion AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Xvivo Perfusion AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	545.788	/	(10.268	+	21.169)
	=	17.36

Xvivo Perfusion AB's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	511.153	/	(10.996	+	19.914)
	=	16.54

Xvivo Perfusion AB (OSTO:XVIVO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Xvivo Perfusion AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB (OSTO:XVIVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OSTO:XVIVO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

XVIPF:USA 3XV:Germany

Address

Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (OSTO:XVIVO) Headlines

No Headlines